1. Home
  2. RXRX vs LMAT Comparison

RXRX vs LMAT Comparison

Compare RXRX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.50

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$112.42

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXRX
LMAT
Founded
2013
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
RXRX
LMAT
Price
$3.50
$112.42
Analyst Decision
Buy
Buy
Analyst Count
4
5
Target Price
$7.50
$105.80
AVG Volume (30 Days)
10.4M
162.7K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
0.89%
EPS Growth
14.79
30.57
EPS
N/A
2.52
Revenue
$74,681,000.00
$249,602,000.00
Revenue This Year
$12.11
$14.21
Revenue Next Year
$82.52
$8.88
P/E Ratio
N/A
$44.70
Revenue Growth
26.92
13.53
52 Week Low
$2.80
$78.01
52 Week High
$7.18
$118.01

Technical Indicators

Market Signals
Indicator
RXRX
LMAT
Relative Strength Index (RSI) 51.04 54.93
Support Level $2.89 $80.90
Resistance Level $3.99 $113.40
Average True Range (ATR) 0.17 2.74
MACD 0.04 -0.48
Stochastic Oscillator 52.41 49.62

Price Performance

Historical Comparison
RXRX
LMAT

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

Share on Social Networks: